Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Baby cries show evidence of cocaine exposure during pregnancy

  • Bipolar disorder discovery at the nano level

  • Alternate approach to traditional CPR saves lives

  • Teenage self-harm linked to problems in later life

  • Unsteady on your feet? Little touches could make all the difference

  • Genes exhibit different behaviours in different stages of development

  • Susceptibility for relapsing major depressive disorder can be calculated

  • Clinical trial could change standard treatment for stroke

  • Criminologists try to solve murder mystery: Who will become a killer?

  • Association between air toxics, childhood autism

  •